In addition to aggressive lifestyle and nonlipid risk factor modification, statin therapy improves cardiovascular disease outcomes following acute coronary syndromes. Despite established benefits of treatment, contemporary registries reveal substantial underutilization of and nonadherence to statin therapy for secondary prevention. In randomized controlled trials investigating statin therapy, including moderate-intensity statin plus ezetimibe therapy, rates of nonadherence are reported in up to 40% of subjects. Durable strategies to address gaps in lipid lowering for secondary prevention are essential to maximize reduction in cardiovascular disease risk. (J Am Coll Cardiol 2015;66:184-92)
and other apolipoprotein-B-containing lipoproteins, reduces arterial inflammation, stabilizes the lipid core, and promotes regression of atherosclerosis (1, 2) . Randomized clinical trials (RCTs) have shown that statin therapy reduces cardiovascular disease (CVD) events by 25% to 40% and that these benefits accrue within the first 6 months after ACS (3, 4) .
Consequently, high-intensity statin therapy before hospital discharge after ACS is a Class I, Level of Evidence: A guideline-recommendation, irrespective of baseline LDL-C level (5) .
Despite these established benefits, contemporary registries reveal substantial underutilization of and nonadherence to statin prescriptions for secondary prevention after ACS. In RCTs investigating the efficacy of statin therapy on CVD outcomes after ACS, including the recently reported IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial), up to 40% of patients discontinued the study medication prematurely (6) .
Clinical practice registries demonstrate even higher nonadherence rates. Other clinical trials and registries have reported higher mortality rates following discontinuation of statin therapy after ACS (2,7).
Suboptimal pharmacologic LDL-C lowering after ACS can be attributed to statin underutilization ( Table 1) and to medication nonadherence (Tables 2 and 3) .
UNDERUTILIZATION OF STATIN THERAPY AFTER ACS: CONTEMPORARY EVIDENCE
In a recent issue of the Journal, Maddox et al. (8) The statin dose prescribed after ACS is also a concern. A separate publication in the Journal examined a sample of Medicare beneficiaries who were prescribed a statin at discharge following a hospitalization for ACS from 2007 to 2009 (10) . Only 27.0% of prescriptions filled were for a high-intensity statin, which increased to only 35% within 365 days from the discharge date. Among patients not taking statins before admission, 23.1% were prescribed a high-intensity statin at discharge. Only 9.4% of patients treated with a low-to moderate-intensity statin before admission were prescribed a highintensity statin at discharge. In contrast, 80.7% of patients treated with a high-intensity statin before admission were prescribed the high-intensity dose at discharge.
Other registries have reported similar findings. In the United States and Europe, 23% to 38% of patients hospitalized for MI are prescribed maximal-intensity statin therapy at discharge (11) (12) (13) ). An observational study of Table 2) .
The highest annual rates of statin discontinuation were reported in the A to Z (Aggrastat to Zocor) (19) and PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) (14) trials, with >30% of patients discontinuing therapy over the course of follow-up. In the majority (55%) of cases in the A to Z trial, the study statin was discontinued due to physician or patient preference, with adverse experiences or events accounting for 28% of premature discontinuation (19) . In the PROVE IT-TIMI 22 study, only 5.3% of patients discontinued the study atorvastatin dose due to laboratory abnormalities or side effects; the remainder stopped due to patient or physician preference (14) . In-depth focus on the rationale for premature study drug discontinuation in clinical trials, commonly ascribed to patient or physician preference, may inform explanations for statin discontinuation in routine clinical practice. In large, real-world registries of patients with CHD, adherence to statin therapy is even lower than in clinical trials and can reach 50% at 1 year ( Table 3) .
In addition to statin underutilization, nonadherence to lipid-lowering therapy for secondary prevention remains an important obstacle to CVD event reduction (Central Illustration).
Adherence refers to the extent to which a patient's medication-taking practice coincides with prescribed medical recommendations (20) . Although many patient characteristics can affect statin efficacy, nonadherence is among the most important determinants of outcome. Rasmussen et al. (21) demonstrated that increasing levels of statin adherence are inversely associated with LDL-C and mortality after ACS. Only 50% to 60% of patients remain adherent within 1 year of initiation, declining to 30% to 40% at 2 years (22, 23) . Nonadherence is multifactorial and is influenced by demographic and socioeconomic factors, lifestyle habits, time since last provider visit, adverse effects of therapy, and complex medication regimens (24) .
Nonadherence affects all guideline-directed medical therapy, including LDL-C-lowering therapy. A multimodality, systems-based, incentive approach may be necessary to overcome these barriers. 
MEASURING ADHERENCE
Providers are currently not adept at recognizing nonadherence (25) . In qualitative studies, providers did not inquire about adherence in one-third of patients with poor blood pressure control (26, 27) , suggesting a need for broader recognition of the importance of nonadherence to outcomes, which will be increasingly linked to provider payment, posing both new challenges and opportunities. Measuring nonadherence is challenging, requiring integration of health services at multiple levels. Currently, adherence is inferred on the basis of pill counts, blister packs, and patient questionnaires or self-reports, such as diaries. Questioning of patients during provider visits or through questionnaires can be susceptible to misrepresentation and tend to overestimate adherence (25, 26) . Pill counts, another common approach to assess medication adherence, appear to be simple and objective. However, patients can switch medicines between bottles and may have an insufficient or excess quantity of pills that can influence accuracy (26, 27) . Despite these biases, poorer adherence, as measured by these methods, has been associated with adverse CVD events (24, 27 ).
Electronic monitoring devices and event monitors
that record the timing and opening of bottles provide more reliable data on adherence dynamics over Abbreviations as in Table 1 . 
ADVERSE EFFECTS OF LIPID-LOWERING THERAPY
Statin intolerance and concerns regarding adverse effects of statin therapy contribute to nonadherence.
Many patients may be reluctant to begin statin therapy due to concern for developing adverse events. In RCTs, statin therapy causes only a slight increase in side effects compared with placebo. Statin intolerance ranges from approximately 1% to 10% in RCTs, to as high as 10% to 25% in observational studies (33, 45) .
Myalgia, the most common reason for discontinuation, occurs with similar frequency in both placebo and treatment arms (45, 46 
